Company intelligence / Profile preview

Liom Health AG

Pfäffikon, Schwyz, Switzerlandliom.com ↗

Ownership: Private
Employees: ~80
Development stage: Preclinical

Overview

Liom has developed a non-invasive wearable for continuous glucose monitoring using spectroscopic and AI-based technology. Internal and third-party studies in 2024 with over 60 subjects demonstrated a MARD of 14.5% without per-subject calibration and as low as 7% with calibration—comparable to first-generation needle-based CGMs. The company is preparing for larger-scale testing (>100 people by end of 2025) and aims to launch pre-sales in early 2026 with commercial availability by mid–2027.

Therapeutic areas: OtherEndocrinologyInfectious Diseases
Modalities: DeviceAI-driven diagnosticsSpectroscopic measurement platform
Industry: Physiological Monitoring

Partnerships

No specific major pharma or biotech partnerships disclosed.

Beyond the preview

Go deeper on Liom Health AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liom Health AG.

Explore the full profile